| Dr Matt N Bien, MD | |
|
400 22nd Ave, Brookings, SD 57006-2450 | |
| (605) 697-9500 | |
| (605) 697-6939 |
| Full Name | Dr Matt N Bien |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 28 Years |
| Location | 400 22nd Ave, Brookings, South Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972553949 | NPI | - | NPPES |
| 6003832 | Medicaid | SD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 4741 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brookings Health System | Brookings, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| City Of Brookings | 1052307105 | 85 |
| Rural Health Care Inc | 3476447541 | 130 |
News Archive
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
A gluten-free, casein-free diet may lead to improvements in behavior and physiological symptoms in some children diagnosed with an autism spectrum disorder (ASD), according to researchers at Penn State. The research is the first to use survey data from parents to document the effectiveness of a gluten-free, casein-free diet on children with ASD.
You could call it paying it forward. A trip to the Emergency Department (ED) is every parent's worst nightmare. But what if the information documented as a result of your child's visit could help a child with similar symptoms a few provinces away? Terry Klassen and his research team of leading pediatric emergency physicians at Pediatric Emergency Research of Canada (PERC) have done just that and the impact of their research is today recognized as one of the Top Canadian Achievements in Health Research in 2011.
Throughout her 20-year career as a nurse practitioner, Jennifer Hulett noticed survivors of breast cancer would often express gratitude for being alive and mention God or a divine acknowledgement that had improved their health and well-being.
What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by researchers from Heidelberg University Hospital (UKHD) and the Medical Faculty of Heidelberg, the DZIF and other partners, has now been approved by the European Commission.
› Verified 9 days ago
| Entity Name | Rural Health Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720076441 PECOS PAC ID: 3476447541 Enrollment ID: O20040210000648 |
News Archive
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
A gluten-free, casein-free diet may lead to improvements in behavior and physiological symptoms in some children diagnosed with an autism spectrum disorder (ASD), according to researchers at Penn State. The research is the first to use survey data from parents to document the effectiveness of a gluten-free, casein-free diet on children with ASD.
You could call it paying it forward. A trip to the Emergency Department (ED) is every parent's worst nightmare. But what if the information documented as a result of your child's visit could help a child with similar symptoms a few provinces away? Terry Klassen and his research team of leading pediatric emergency physicians at Pediatric Emergency Research of Canada (PERC) have done just that and the impact of their research is today recognized as one of the Top Canadian Achievements in Health Research in 2011.
Throughout her 20-year career as a nurse practitioner, Jennifer Hulett noticed survivors of breast cancer would often express gratitude for being alive and mention God or a divine acknowledgement that had improved their health and well-being.
What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by researchers from Heidelberg University Hospital (UKHD) and the Medical Faculty of Heidelberg, the DZIF and other partners, has now been approved by the European Commission.
› Verified 9 days ago
| Entity Name | City Of Brookings |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932281029 PECOS PAC ID: 1052307105 Enrollment ID: O20040423000002 |
News Archive
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
A gluten-free, casein-free diet may lead to improvements in behavior and physiological symptoms in some children diagnosed with an autism spectrum disorder (ASD), according to researchers at Penn State. The research is the first to use survey data from parents to document the effectiveness of a gluten-free, casein-free diet on children with ASD.
You could call it paying it forward. A trip to the Emergency Department (ED) is every parent's worst nightmare. But what if the information documented as a result of your child's visit could help a child with similar symptoms a few provinces away? Terry Klassen and his research team of leading pediatric emergency physicians at Pediatric Emergency Research of Canada (PERC) have done just that and the impact of their research is today recognized as one of the Top Canadian Achievements in Health Research in 2011.
Throughout her 20-year career as a nurse practitioner, Jennifer Hulett noticed survivors of breast cancer would often express gratitude for being alive and mention God or a divine acknowledgement that had improved their health and well-being.
What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by researchers from Heidelberg University Hospital (UKHD) and the Medical Faculty of Heidelberg, the DZIF and other partners, has now been approved by the European Commission.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matt N Bien, MD 400 22nd Ave, Brookings, SD 57006-2450 Ph: (605) 697-9500 | Dr Matt N Bien, MD 400 22nd Ave, Brookings, SD 57006-2450 Ph: (605) 697-9500 |
News Archive
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
A gluten-free, casein-free diet may lead to improvements in behavior and physiological symptoms in some children diagnosed with an autism spectrum disorder (ASD), according to researchers at Penn State. The research is the first to use survey data from parents to document the effectiveness of a gluten-free, casein-free diet on children with ASD.
You could call it paying it forward. A trip to the Emergency Department (ED) is every parent's worst nightmare. But what if the information documented as a result of your child's visit could help a child with similar symptoms a few provinces away? Terry Klassen and his research team of leading pediatric emergency physicians at Pediatric Emergency Research of Canada (PERC) have done just that and the impact of their research is today recognized as one of the Top Canadian Achievements in Health Research in 2011.
Throughout her 20-year career as a nurse practitioner, Jennifer Hulett noticed survivors of breast cancer would often express gratitude for being alive and mention God or a divine acknowledgement that had improved their health and well-being.
What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by researchers from Heidelberg University Hospital (UKHD) and the Medical Faculty of Heidelberg, the DZIF and other partners, has now been approved by the European Commission.
› Verified 9 days ago
Dr. Gerald L. Turner, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 400 22nd Ave., Brookings, SD 57006 Phone: 605-697-9500 Fax: 605-697-6939 | |
Dr. Tatiana B Sergeev, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 400 22nd Ave., Brookings, SD 57006 Phone: 605-697-9500 Fax: 605-697-6939 |